Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04745559 · ClinicalTrials.gov registry record · Phase 2
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
A Phase 2 study of Follicular Lymphoma and Primary Mediastinal Large B-cell Lymphoma (PMBCL), sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT04745559: Active Phase 2 study of Follicular Lymphoma and Primary Mediastinal Large B-cell Lymphoma (PMBCL), sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT04745559 is a Phase 2 study of Follicular Lymphoma and Primary Mediastinal Large B-cell Lymphoma (PMBCL) that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 26 participants, below the 135-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04745559, a Phase 2 study of Follicular Lymphoma and Primary Mediastinal Large B-cell Lymphoma (PMBCL), is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate whether receiving the pneumococcal 13-valent conjugate vaccine (PCV13) before and after CD19-targeted CAR T cell therapy will optimize cellular and humoral immunity to pneumococcus.
Primary Outcome
Humoral sero-protection rate elicited by the PCV13 vaccine intervention as measured on day+90 post CART
Conditions Studied
Interventions
- BIOLOGICAL Pneumococcal conjugate vaccine (PCV13)
- BIOLOGICAL CD19 targeted CAR T Cell Therapy
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2021-02-18 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
What the registry record for NCT04745559 still lists
NCT04745559 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 135-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (81% lower).
The record links to 5 conditions, with Follicular Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Pneumococcal conjugate vaccine (PCV13) is the first listed.
NCT04745559 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04745559 about?
NCT04745559 is a clinical study titled "Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy". The purpose of the study is to evaluate whether receiving the pneumococcal 13-valent conjugate vaccine (PCV13) before and after CD19-targeted CAR T cell therapy will optimize cellular and humoral immunity to pneumococcus.
What is the current status of trial NCT04745559?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2021-02-18. Estimated completion is 2027-06.
What conditions does trial NCT04745559 study?
This clinical trial studies the following conditions: Follicular Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Diffuse Large Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Transformed Follicular Lymphoma (tFL).
What interventions are being tested in trial NCT04745559?
The interventions under investigation include: Pneumococcal conjugate vaccine (PCV13) (BIOLOGICAL), CD19 targeted CAR T Cell Therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT04745559?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04745559 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04745559's enrollment target sits among peer trials
26 75th of 89 higher than 14 of 89 other Follicular Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Follicular Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
RECRUITING · Phase 2
-
Epcoritamab and Rituximab for First-line Follicular Lymphoma
RECRUITING · Phase 2
-
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI